Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature
Open Access
- 1 June 2020
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 190 (2), 185-188
- https://doi.org/10.1111/bjh.16896
Abstract
Background COVID‐19 is an emerging infectious disease caused by SARS‐CoV‐2. The role of immunosuppression in disease course is not clear. Here we describe the lethal disease course in two SARS‐CoV‐2 infected patients after rituximab therapy. Methods Clinical data and laboratory findings of two SARS‐CoV‐2 infected rituximab treated patients were collected. SARS‐CoV‐2 RNA was detected in blood. Results Both patients developed severe respiratory failure. SARS‐CoV‐2 viremia persisted in both patients until they died on day 22 and 26 after admission. Conclusion Rituximab therapy leads to severe combined immunodeficiency and these two cases indicate a high risk for fatal outcome after SARS‐CoV‐2 infection.This publication has 15 references indexed in Scilit:
- Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recoverPediatric Allergy and Immunology, 2020
- Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort studyBMJ, 2020
- Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #FlatteningthecurveAmerican Journal of Transplantation, 2020
- The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nature Microbiology, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCREurosurveillance, 2020
- Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmissionThe Lancet Infectious Diseases, 2018
- Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic LeukemiaCancer Research and Treatment, 2017
- Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506Virus Research, 2012
- Host response to influenza virus: protection versus immunopathologyCurrent Opinion in Immunology, 2010